This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 1
  • /
  • FDA approves expansion of indication for Enhertu i...

FDA approves expansion of indication for Enhertu in metastatic HER2-positive gastric or gastroesophageal adenocarcinoma.- AstraZeneca/Daiichi Sankyo

Read time: 1 mins
Published:17th Jan 2021
AstraZeneca and Daiichi Sankyo have announced that the FDA has approved label expansion for Enhertu (fam-trastuzumab deruxtecan-nxki) to include adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma that would have previously been treated with a trastuzumab-based regimen. The therapy was granted an accelerated approval in 2019 to treat unresectable HER2-positive breast cancer in patients who have received at least two prior anti-HER2-based regimens in the metastatic setting. This application, which was assessed under a priority review, was supported by data from the Phase II DESTINY-Gastric01 trial involving 126 patients with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma who had progressed on at least two prior regimens, including trastuzumab, a fluoropyrimidine- and a platinum-containing chemotherapy.
Condition: Gastric Cancer/Stomach Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.